During the 2023 edition of the GFN, a pool of international diabetologists, coordinated by prof. Riccardo Polosa, addressed the issue of cigarette smoking among diabetes patients, setting new international treatment

GFN 2023 will start tomorrow in Varsavia. The 10th edition of the Global Forum on Nicotine, organised from 21st to 24th June, will host events dedicated to harm reduction research.

Diabetes is a chronic disease that can be the cause of serious health conditions and greatly reduce people quality of life. Conventional cigarette smoke is a very high risk factor

Diasmoke 2.0 is a CoEHAR research project that aims to assess health improvements and changes in cardiovascular risk factors in smokers with Type 2 Diabetes who switch to combustion-free nicotine

A recent randomized controlled trial of varenicline (Chantix) combined with psychological support has significantly increased the chance of quitting smoking for 300 smokers with type 2 diabetes mellitus LINK TO

LINK TO THE STUDY  Quitting smoking can reduce cardiovascular and kidney failure risks. However, it can lead to side effects such as weight gain. A scoping review conducted by a

“This agreement means capitalizing the scientific potential of our universities, investing in young people and their future” said prof. Emil Ceban. Catania,17th November 2021. Academic cooperation between the Center of

With the first subjects enrolled, the Diasmoke project has entered the recruitment phase. The main goal of the project by CoEHAR is to determine whether smokers with diabetes mellitus- who

On Monday 22 March from 9.30 to 17.00 CET, on the Zoom platform, the CoEHAR (Center of Excellence for the acceleration of Harm Reduction) will hold the kick off meeting